<SEC-DOCUMENT>0000947871-23-001158.txt : 20231215
<SEC-HEADER>0000947871-23-001158.hdr.sgml : 20231215
<ACCEPTANCE-DATETIME>20231215181817
ACCESSION NUMBER:		0000947871-23-001158
CONFORMED SUBMISSION TYPE:	144/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20231215
DATE AS OF CHANGE:		20231215

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Disc Medicine, Inc.
		CENTRAL INDEX KEY:			0001816736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851613057
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39438
		FILM NUMBER:		231491738

	BUSINESS ADDRESS:	
		STREET 1:		321 ARSENAL STREET, SUITE 101
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 674-9274

	MAIL ADDRESS:	
		STREET 1:		321 ARSENAL STREET, SUITE 101
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemini Therapeutics, Inc. /DE
		DATE OF NAME CHANGE:	20210209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FS Development Corp.
		DATE OF NAME CHANGE:	20200702

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORBIMED ADVISORS LLC
		CENTRAL INDEX KEY:			0001055951
		IRS NUMBER:				133976876
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		144/A

	BUSINESS ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 739-6400

	MAIL ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>144/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144/A</submissionType>
    <previousAccessionNumber>0000947871-23-001139</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
          <cik>0001055951</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001816736</issuerCik>
      <issuerName>Disc Medicine, Inc.</issuerName>
      <secFileNumber>001-39438</secFileNumber>
      <issuerAddress>
        <com:street1>321 Arsenal Street, Suite 101</com:street1>
        <com:city>Watertown</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02472</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-674-9274</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Genesis Master Fund, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Themis Trading LLC</name>
        <address>
          <com:street1>10 Townsquare</com:street1>
          <com:city>Chatham</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07928</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>121840</noOfUnitsSold>
      <aggregateMarketValue>7437114.00</aggregateMarketValue>
      <noOfUnitsOutstanding>24140428</noOfUnitsOutstanding>
      <approxSaleDate>12/12/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Morgan Stanley</name>
        <address>
          <com:street1>1585 Broadway</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10036</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>121840</noOfUnitsSold>
      <aggregateMarketValue>7437114.00</aggregateMarketValue>
      <noOfUnitsOutstanding>24140428</noOfUnitsOutstanding>
      <approxSaleDate>12/12/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>12/29/2022</acquiredDate>
      <natureOfAcquisitionTransaction>Business Combination</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>121840</amountOfSecuritiesAcquired>
      <paymentDate>12/29/2022</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC. This amended Form 144 is being filed to add Morgan Stanley as an additional broker.</remarks>
    <noticeSignature>
      <noticeDate>12/15/2023</noticeDate>
      <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
